US 12,668,921

Application 18/129,216 · Granted Jun 30, 2026

Flow-optimized edge treatment

Estimated expiration

December 27, 2042

16y 39d remaining

Confidence: high
High: no high-severity warning was raised, and any terminal disclaimer was resolved to the patents it references.
  • Could not fetch continuity data for application PCTEP2021075418: Resource not found (404)
Earliest effective filing
Sep 16, 2021
+ 20 years
Sep 16, 2041
PTA +467d
Dec 27, 2042
No TD
—
Final
Dec 27, 2042

This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included.

Calculation details

Base term

Filing date
March 31, 2023
Earliest effective filing
September 16, 2021
Issue date
June 30, 2026
PTA
+467 days
Base expiry (before PTA)
September 16, 2041

September 16, 2021 + 20 years = September 16, 2041 + 467 PTA days = December 27, 2042

  • Continuation of application PCTEP2021075418, filed Sep 16, 2021

Terminal disclaimers

No TD0 approved, 0 filed

Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated

You have the date. Your AI can have the file.

Application 18/129,216 · US 12,668,921

PatentReply compiles the prosecution history behind US 12,668,921: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.

One new published application a month is free. The first compile takes a few minutes.

Strategy and filing changes require your approval.

How PatentReply handles an Office Action response →

Permanent link

www.patentreply.ai/tools/patent-expiration/US12668921

Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.